Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.01 0.25 (2.13%) Market Cap: 527.03 Mil Enterprise Value: 442.37 Mil PE Ratio: 0 PB Ratio: 5.31 GF Score: 0/100

Y-mAbs Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2022 / 02:00PM GMT
Release Date Price: $13.77 (-3.91%)
Tessa Thomas Romero
JPMorgan Chase & Co, Research Division - Associate

Welcome, everyone to the 40th Annual JPMorgan Healthcare Conference. My name is Tessa Romero, I'm one of the senior biotech analyst here at JPMorgan, and I'm joined by Taylor Hamley from the team. Our next presenting company is Y-mAbs Therapeutics. And presenting on behalf of the company, we have CEO, Claus Møller. Before I hand it over to Claus, I just wanted to remind all of our listeners to please use the ask-a-question button to submit any questions, and I'm happy to ask on your behalf.

With that, I will turn it over to Claus.

Claus Juan MÃ;ller;San Pedro
Y-mAbs Therapeutics, Inc. - CEO & Director

¸- -

Thank you very much, Tessa, and thank you, everybody, for listening in today. It's my pleasure to give the Y-mAbs company presentation here in January 2022 at the JPMorgan conference. Unfortunately, it's virtual and not for real, but I hope we will be seeing each other, everybody in January next year.

With this disclaimer, I think

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot